Becton, Dickinson and Co. | BDX - Cost Of Sales


Becton, Dickinson and Co. reported $2.56B in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Abbott USD 5.3B 380M Mar/2026
Agilent USD 845M 7M Mar/2026
Align Technology USD 303.5M 60.47M Mar/2026
AngioDynamics USD 37.29M 786K Sep/2025
Avanos Medical USD 88M 6.9M Mar/2026
Baxter International USD 1.81B 587M Mar/2026
Becton, Dickinson and Co. USD 2.56B 281M Mar/2026
Bio-Rad Laboratories USD 348M 38.4M Dec/2025
Boston Scientific USD 1.83B 8M Mar/2026
Cooper Companies USD 393.8M 17M Mar/2026
Danaher USD 2.36B 512M Mar/2026
Dentsply International USD 453M 65M Mar/2026
Dexcom USD 441.6M 25.3M Mar/2026
Edwards Lifesciences USD 362.6M 19.6M Mar/2026
Globus Medical USD 263.59M 26.88M Mar/2026
Insulet USD 232.7M 17.5M Mar/2026
Integra LifeSciences USD 178.71M 14.73M Mar/2026
Intuitive Surgical USD 940.3M 21.6M Mar/2026
J&J USD 8.07B 103M Mar/2026
Medtronic USD 3.8B 195M Mar/2026
Solventum Corp USD 911M 60M Mar/2026
Stryker USD 2.36B 325M Mar/2026
Tandem Diabetes Care USD 122.92M 7.96M Dec/2025
Teleflex USD 240.84M 20.7M Mar/2026
Terumo JPY 151.3B 7.86B Mar/2026
Thermo Fisher Scientific USD 6.96B 620M Mar/2026
Zimmer Biomet Holdings USD 738.3M 231.8M Mar/2026